A brief report of toxicity end points of HER2 vaccines for the treatment of patients with HER2+ breast cancer

Ricardo Costa1
Saif Zaman2
Susan Sharpe3
Irene Helenowski4
Colleen Shaw1
Hyo Han1
Hatem Soliman1
Brian Czerniecki1

1Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; 2Morsani College of Medicine, University of South Florida, Tampa, FL, USA; 3Moffitt Biomedical Library, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; 4Department of Preventive Medicine, Northwestern University, Chicago, IL, USA

Abstract: Human epidermal growth factor receptor 2 (HER2)-targeted vaccines are under development, but have so far demonstrated only modest clinical efficacy. Additionally, there has been a lack of adequate safety assessment in large-scale prospective clinical trials. Therefore, we performed a meta-analysis of available clinical trial data to summarize the toxicity profiles of these treatments. Literature search was conducted in February 2018. The trials analyzed had at least one study arm consisting of HER2 vaccine monotherapy. Heterogeneity across studies was analyzed using I2 statistics. Data were analyzed using random-effects meta-analysis for absolute risk (AR). Eight trials and 248 patients were included. There was no evidence of heterogeneity between studies for grades 3/4 adverse events (AEs) or for death. The AR for treatment-related serious AEs was 5% with no treatment-related deaths. The AR of all-grade fatigue, injection site reaction, and fever/chills/rigors was 33%, 23%, and 31%, respectively. Asymptomatic drop in left ventricle ejection fraction was rare (8%). HER2 vaccines are well tolerated with increased AR of fatigue, injection site reactions, and fever/chills/rigors.

Keywords: HER2, vaccines, immunity, dendritic cells, toxicity

Introduction
Breast cancer is a heterogeneous disease the classification of which is immunohistochemically defined by the presence of hormonal receptors for estrogen, progesterone, and the expression/amplification status of the human epidermal growth factor receptor 2 (HER2) protein/oncogene.1,2 Systemic passive immune treatment directed to the HER2 oncoprotein leads to meaningful improvement in clinical outcomes among the subset of patients with breast tumors harboring HER2 overexpression/amplification. HER2-targeted antibodies (ie, trastuzumab and pertuzumab) combined with docetaxel improve the median overall survival (MOS) of patients with HER2-positive (HER2+) metastatic breast cancer (MBC) to 56.5 months; historically, patients treated with chemotherapy alone have an estimated MOS of 20.3 months.3,4 Notwithstanding recent advances, patients with HER2+ MBC will eventually acquire resistance to HER2-targeted therapies and disease progression will ensue. Furthermore, a subset of patients with HER2+ resectable breast cancer will have disease recurrence despite multimodal treatment.5

Next-generation sequencing has led to a better understanding of genomic alterations in HER2+ breast cancer. It is remarkable that the vast majority of the aberrations appreciated in these tumors are observed at low frequencies (at <5%, except for PIK3CA [39%] and P53 [72%]).6 This advancement has allowed for the design of studies assessing the efficacy of drugs that target specific mechanisms of resistance to...
HER2-targeted therapies. In this setting, the development of immune oncology treatment has gained momentum based on the premise that activation of adaptive cellular immunity can lead to significant anti-tumor activity and clinical benefit. Activation of the adaptive branch of the immune system can be initiated via several mechanisms (ie, immune checkpoint inhibitors, adoptive T-cell transfer, and cytokine infusion). These strategies remain, however, in their initial stages of clinical development for the treatment of HER2+ breast cancer patients. It should be noted that thus far, randomized clinical trials have shown only modest activity of targeted therapies in the setting of disease progression after HER2-targeted treatments. Furthermore, in the Phase Ib/II trial PANACEA, for example, a monoclonal anti-programmed cell death protein 1 antibody, pembrolizumab, was tested in combination with trastuzumab among 58 female patients with trastuzumab-resistant HER2+ MBC (presented at San Antonio Breast Cancer Symposium, 2017). Preliminary results of the Phase II portion of the trial showed an overall response rate of 15% among patients with programmed death-ligand 1 (PD-L1)-positive tumors; no responses were observed among patients with PD-L1-negative tumors. The median duration of disease control was 11.1 months, suggesting significant clinical benefit of the treatment combination among a subset of patients with HER2+ MBC refractory to HER2-targeted therapies when compared with historical controls treated with ado-trastuzumab emtansine alone.

Active immune therapy with vaccines is an attractive treatment modality as it presents a potentially self-sustained strategy for activation of the immune system, encompassing not only cellular but also humoral components. In addition, the therapy can provoke interactions with the innate immune system, leading to antitumor activity that is not limited to the adaptive immune system, and it may also produce epitope spreading and activation of immune response against other tumor-associated or tumor-specific antigens. Thus far, HER2 vaccines have shown only modest clinical efficacy among patients with HER2+ breast cancer. There is also a lack of large prospective trials assessing the safety of these treatments. Hence, the goal of this systematic review and meta-analysis is to better define the toxicity profile of the HER2-directed vaccines among patients with HER2+ breast cancer.

Methods

Search strategy

A systematic literature search was performed in February 2018 by a medical librarian, using MEDLINE via PubMed (1946–2018), Embase (1947–2018), and the Cochrane Library. All publication dates were included (Tables S1–S4). Selected manuscripts were uploaded to the Covidence online platform at www.covidence.org for the purposes of managing references, identifying and removing duplicates, and reviewing titles and abstracts.

Selection of trials and data extraction

There were two inclusion criteria for clinical trials. First, they were required to be any-phase trials among patients with HER2+ breast cancer. HER2+ breast cancer is defined by HER2 overexpression in tumor tissue (eg, HER2 overexpression with immunohistochemistry score 3+) and/or HER2 amplification in tumor tissue (eg, HER2 gene amplification in the primary tumor or metastatic lesion, as determined by fluorescence in situ hybridization [ratio ≥ 2 and HER2 copy number ≥ 4 define HER2+ disease]). Second, the trials must have used HER2 vaccines as monotherapy to be included. Pediatric clinical trials and studies assessing the efficacy of HER2 vaccines in combination with other treatments were excluded.

From manuscripts meeting inclusion criteria, we extracted the total number of: 1) patients evaluable for toxicity, 2) all-grade AEs, 3) grades 3/4 toxicities, 4) deaths, and 5) patients who discontinued treatment due to toxicities. The number of selected all-grade AEs was also documented (ie, fatigue, nausea, diarrhea, fever, injection site reaction, symptomatic congestive heart failure, and asymptomatic drop in left ventricle ejection fraction [LVEF]). These AEs were selected because they represent the most commonly observed AEs that are associated with HER2-targeted monoclonal antibodies or because of their clinical relevance. The relationship between AEs and treatment administration (ie, treatment-related AEs vs all-causality AEs) was also documented when the information was available. Data extraction was first performed by one primary reviewer and then independently reviewed by one secondary reviewer following PRISMA guidelines.

Statistical methods

Meta-analyses were conducted using one-sample proportions to obtain the pooled fixed-effect and random-effect estimates. Heterogeneity was assessed via the I² statistic and publication bias was evaluated via the Egger test. Finally, using the Cochran Q test, we also determined between-studies heterogeneity caused by differences in subsets of tumor type, line of therapy, treatment, and participant age and performance statuses. All analyses were conducted using R 3.3.3 software package.
Results
Included and excluded studies
Our librarian-guided literature search yielded 1,114 publications obtained through PubMed, EMBASE, and Cochrane. Nine hundred and fifty-two studies were excluded during the title and abstract screening on the basis of their not being prospective randomized trials (Figure 1). After text review, 93 additional studies were excluded for not meeting the inclusion criteria. Eight studies met the inclusion criteria and data from them were extracted (Table 1). These studies included three Phase II trials, and six of the eight studies investigated HER2-directed dendritic cell (DC1) vaccines in breast cancer stages 0–IV. None of the eight trials reported the median follow-up time in their data presentation, nor did they clearly state the causality of reported AEs.

Description of study participants
In the eight studies, a total of 248 patients were evaluable for toxicity, 60 of whom had stage IV breast cancer. The median age of study participants was only reported in three studies (50–60 years of age).

Study-to-study heterogeneity and publication bias
$F^2$ statistics revealed that inter-study heterogeneity was 0% for grades 3/4 AEs ($P=0.63$) and 10% for serious AEs ($P=0.34$). There was no significant heterogeneity associated with the outcome of death. Heterogeneity testing for selected grades 3/4 AEs is presented in Table 2. Testing for publication bias did not show significant results.

Number of all-grade AEs, grades 3/4 AEs, serious AEs, treatment-related deaths, and number of patients who discontinued treatment due to toxicity
The total number of all-grade AEs was not meta-analyzed because only a few trials had reported them (two of the eight studies). Eight grades 3/4 AEs were observed among the 248 patients, and there was an estimated pooled absolute risk (AR) of 6% (95% CI, 3–10). Four out of eight patients presenting with grade 3 AEs had AEs that were classified as possibly treatment related (ie, injection site reaction, fatigue, diarrhea, and asthenia). There were no reports of grade 4...
treatment-related AEs. All eight studies reported the number of patients who discontinued treatment because of toxicities, and none had done so.

Data on serious AEs were available in four of the eight studies, and the random- and fixed-effects pooled AR risk of serious AEs was 5% (95% CI, 2–10) (Figure 2). A total of six treatment-related AEs were reported. These were fatigue, malaise, influenza-like symptoms, hypotension, and two episodes of pyrexia. All eight studies reported that there were no treatment-related deaths.

Number of all-grade selected toxicities
The most common all-grade toxicities were fever, chills, and rigors, with a random-effect absolute risk of 31% (95% CI, 13–56), followed by fatigue, with a random-effect AR of 28% (95% CI, 12–53) (Table 2). A pooled analysis of injection site reaction showed a pooled AR of 23% for all-grade reactions. Nonetheless, the fixed-effect AR of an asymptomatic drop in LVEF was 8% (95% CI, 6–13). Of note, no symptomatic drop in LVEF was reported.

| PMID      | First author | Study phase | Stage               | Evaluable patients, N | Vaccine type | Vaccine adjunct | NCI CTCAE grading | Echo/MUGA performed during study |
|-----------|--------------|-------------|---------------------|------------------------|--------------|----------------|-------------------|-----------------------------|
| 17293384  | Czerniecki   | ii          | DCiS and microinvasive | 13                     | DCs          | NA             | NR                | NR                          |
| 27965306  | Lowenfeld    | ii          | DCiS and I–III      | 54                     | DCs          | NA             | NR                | Yes                         |
| 22252842  | Sharma       | I           | DCiS                | 29                     | DCs          | NA             | NR                | Yes                         |
| 26975189  | Curigliano   | ii          | Stage IV            | 40                     | dHER2        | AS15           | NR                | Yes                         |
| 17822557  | Morse        | Pilot       | Stages I–IV         | 6                      | DCs          | NA             | NR                | Yes                         |
| 22130160  | Koski        | Pilot       | DCiS                | 27                     | DCs          | NA             | NR                | Yes                         |
| 17704416  | Park         | I           | Stage IV            | 18                     | DCs          | NA             | NR                | Yes                         |
| 26993131  | Limentani    | I           | Stages I–III        | 61                     | dHER2        | NA             | 2                  | Yes                         |

Notes: *Number of patients with Eastern Cooperative Oncology Group performance status 2 was not reported in any study. †Cardiac toxicity end points for trial published by Koski et al were republished in Bahl et al (PMID: 19800453).

Abbreviations: DCs, dendritic cells; DCiS, ductal carcinoma in situ; dHER2, a truncated recombinant HER2/neu peptide; Echo, echocardiogram; MUGA, multigated acquisition scan; NA, not applicable; NCI CTCAE, National Cancer Institute Common Terminology Criteria Adverse Events; NR, not reported; PMID, PubMed identification.

Discussion
In light of the growth of immune therapies for the treatment of solid tumors—as exemplified by the approval of numerous checkpoint inhibitors—the development of active immune therapy with vaccines, alone or in combination, has gained renewed momentum. Although vaccine trials for the treatment of HER2+ breast cancer have hitherto failed to translate clinically meaningful results into daily practice, building a better understanding of the immune milieu may allow for the development of synergistic treatments. For example, in a breast cancer pre-clinical model, blocking the programmed death cell protein/PD-L1 and cytotoxic T-lymphocyte associated protein 4/CD28 molecule pathways with monoclonal antibodies restores antigen-presenting cell function, improves T-cell function (resulting in increased interferon gamma and tumor necrosis factor alpha production), and promotes T-cell proliferation and T-cell targeting of tumors. 13 Collectively, these data suggest that combined vaccines and checkpoint inhibitors could further activate adaptive immune responses against breast cancer cells.

Table 2 AR of selected all-grade AEs

| All-grade AE              | Fixed-effect AR, % (95% CI, range) | Random-effect AR, % (95% CI, range) | P†, %  | P-value |
|--------------------------|-----------------------------------|-----------------------------------|--------|---------|
| Injection site reaction  | 31 (24–39)                        | 23 (9–48)                         | 87     | 0.01    |
| Fever, chills, rigors    | 31 (23–40)                        | 31 (13–56)                       | 83     | 0.01    |
| Fatigue                  | 33 (24–43)                        | 33 (13–56)                       | 83     | 0.01    |
| Nausea†                  | 20 (10–36)                        | 13 (1–73)                        | 91     | 0.01    |
| Diarrhea†                | 5 (2–11)                          | 5 (2–11)                         | 0      | 0.88    |
| Dizziness†               | 7 (3–15)                          | 7 (3–15)                         | 0      | 0.35    |
| Asymptomatic drop in LVEF| 8 (6–13)                          | 8 (6–13)                         | 0      | 0.05    |

Notes: *Percentage of variance between studies that is due to heterogeneity and not by chance. †Data were pooled from two studies that reported outcomes.

Abbreviations: AEs, adverse events; AR, absolute risk; LVEF, left ventricle ejection fraction.
Toxicity end points of HER2 vaccines for HER2+ breast cancer patients

We conducted a systematic review and meta-analysis to refine the assessment of AE risk associated with HER2 vaccines in patients with HER2+. As a systematic review and meta-analysis of clinical trials, this study improves the precision of AE prevalence estimates among these patients. Eight clinical trials met the inclusion criteria of our study (Table 1). Between-study heterogeneity was observed in studies for some of the end points assessed, which can be explained by differences in baseline performance status, tumor stage, prior number of lines of therapy, and types of vaccine used. Treatment with HER2-directed vaccines was well tolerated. Remarkably, no patient discontinued treatment because of treatment-related toxicities, and only four out of 248 patients had treatment-related grade 3 AEs; this was observed among patients with MBC receiving recombinant HER2 protein and immunostimulant AS15. These AEs, which included injection site reaction, fatigue, diarrhea, and asthenia, were considered manageable. HER2-targeted therapy with monoclonal antibodies has been associated with an asymptomatic drop in LVEF or New York Heart Association class II congestive heart failure, with an AR of 0.5%–11%, which is similar to our findings (8% AR) and indicates the favorable cardiac toxicity profile of HER2-directed vaccines.15

Lack of access to individual patient data is the major limitation of this study, preventing further exploration of meaningful correlations between patients’ characteristics and risks of toxicities. Furthermore, in order to minimize between-study heterogeneity and increase the precision of our results, we did not analyze studies that assessed the efficacy of HER2-vaccines combined with HER2-targeted agents. It should be noted, however, that the reported toxicity profile of HER2 vaccines combined with HER2 monoclonal antibodies does not seem to significantly increase the AR of AEs among patients with HER2+ breast cancer. For example, Disis et al reported the results of a Phase I/II trial in which 22 HLA-A2-positive patients with HER2+ MBC, already undergoing treatment with trastuzumab, were treated with major histocompatibility complex classes I and II HER2 epitope vaccines combined with trastuzumab. The treatment combination was well tolerated and was associated

---

### Table 1: AE Risk Estimates for HER2+ Breast Cancer Patients

| Study                   | Events | Total | Proportion | 95% CI          | Weight (fixed) | Weight (random) |
|-------------------------|--------|-------|------------|-----------------|----------------|-----------------|
| Fixed-effect model      | 248    | 0.13  | (0.07; 0.23)| 100%            | –              | 100%            |
| Random-effects model    |        | 0.06  | (0.01; 0.31)| –               | 100%           |                 |

---

Figure 2: Absolute risk of grade 3/4 AEs (A) and absolute risk of serious AEs (B).

Note: - indicates missing data.

Abbreviation: AE, adverse event.
with negligible risk (1%) for grades 3/4 AEs. Additionally, only three treatment-related AEs were reported, including injection-site reaction, ulceration, and fainting.

In summary, treatment with HER2 vaccines is well tolerated and associated with low AR of death and treatment discontinuation caused by treatment-related toxicity. There is increased AR of low-grade infusion site reaction, fever, and fatigue, which do not lead to significant risks of grades 3/4 AEs. Moving forward, the efficacy and safety of HER2 vaccines, such as the dendritic cell vaccine (DC1) and the DNA plasmid-based vaccine (Wokvac), will continue to be developed for the treatment of HER2+ breast cancer (NCT03384914, NCT01730118).

Acknowledgments
We thank Paul Fletcher and Sonya Smyk (Moffitt Cancer Center) for their editorial assistance. They were not compensated beyond their regular salaries. No funding was received for the conduct of this systematic review and meta-analysis.

Disclosure
B Czerniecki has a patent filed for DC1 vaccine and intellectual property license with ImmunoRestoration. The authors report no other conflicts of interest in this work.

References
1. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784–2795.
2. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013.
3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–792.
4. Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724–734.
5. de Azambuja E, Holmes AP, Piccart-Gebhart M, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol. 2014;15(10):1137–1146.
6. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.
7. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639.
8. Reck M, Rodriguez-Abrue D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833.
9. André F, O’Regan R, Ozguerglu M, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014;15(6):580–591.
10. Loi S, Giobbie-Hurder A, Bachelot T. Phase 1b/2 study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive metastatic breast cancer: results from the PANACEA (IBCSG 45-13/ BIG 4-13/KEYNOTE-014) study. San Antonio Breast Cancer Symposium; December 5–9; 2017; San Antonio, TX.
11. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–1791.
12. Costa RLB, Soliman H, Czerniecki BJ. The clinical development of vaccines for HER2+ breast cancer: Current landscape and future perspectives. Cancer Treat Rev. 2017;61:107–115.
13. Ge Y, Xi H, Ju S, Zhang X. Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice. Cancer Lett. 2013;336(2):253–259.
14. Curigliano G, Romieu G, Campone M, et al. A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2016;156(2):301–310.
15. Costa RB, Kurra G, Greenberg L, Geyer CE. Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Ann Oncol. 2010;21(11):2153–2160.
16. Disis ML, Wallace DR, Gooley TA, et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol. 2009;27(28):4685–4692.
Supplementary materials

Table S1 Keywords used in systematic review by category

| HER2 keywords | HER2 vaccine keywords | Breast cancer keywords | Toxicity keywords | Clinical trials keywords* |
|---------------|-----------------------|------------------------|-------------------|---------------------------|
| dHER2         | Her2 Vaccine          | breast cancer          | Receptor, ErbB-2/toxicity[Mesh] | (clinical trials OR “clinical trial” OR Clinical Trial[ptyp] OR “phase I” OR “phase II” OR “phase 2” OR “phase I” OR “phase II” OR “phase I/II” OR Phase I/II OR randomized controlled trial[pt] OR randomized clinical trial[pt] OR randomized[tiab] OR randomised[tiab] OR randomization[tiab] OR placebo[tiab] OR drug therapy[sh] OR randomly[tiab] OR trial[tiab] OR groups[tiab]) NOT (animals[mh] NOT humans[mh]) NOT (Editorial[pt] OR Letter[pt] OR Case Reports[pt] OR Comment[pt]) |
| HER2          | Cancer Vaccines[Mesh] | breast neoplasms       | Cancer Vaccines/adverse effects[Mesh] |
| HER2/neo      | NeuVax                |                        | Cancer Vaccines/administration and dosage[Mesh] |
| “Receptor, ErbB-2”[Mesh] | Peptide cancer vaccines |                        | Toxicity toxicity [Subheading] |
| human epidermal growth factor receptor 2 | peptide vaccines | | |
| 2 her         | Nelipepimut-S         |                        | |
| erb2          | AE37                  |                        | |
| neu Gene      | E75 HER2-derived peptide vaccine, nelipepimut-S | | |
| NEU proto-oncogene | whole cell vaccine | | |
| neu receptor  | CHP-HER2 vaccine      | [Supplementary Concept] | | |
| TKR1          |                      |                        | | |

Note: *Based on the RCT filter from Cochrane.
Abbreviation: RCT, randomized controlled trial.

Table S2 Medical subject headings (MeSH) terms search and synonyms

| Terms               | Search resultsa | Databaseb |
|---------------------|-----------------|-----------|
| Synonyms            |                 |           |
| HER2 vaccine        | 5               | 5         |
| Vaccine             | 74              | 7,677     |
| Vaccination         | 30              | 4,191     |
| Inoculations        | 6               | 141       |
| Immunization        | 5               | 1,492     |
| VACCIN              | –               | 28        |
| HER2                | 74              | 1,956     |
| human epidermal growth factor receptor 2 | 9         | 294       |
| 2 her               | 2               | 5         |
| erb2                | 2               | 168       |
| neu Gene            | –               | 3         |
| NEU proto-oncogene  | –               | 1         |
| neu receptor        | –               | 10        |
| TKR1                | –               | 2         |

Notes: –, No studies found. *Number of studies in the search results containing the term or synonym. †Number of studies in the entire database containing the term or synonym.
### Table S3 PubMed and Embase search strategy and results

| Number | Query | Results* |
|--------|-------|----------|
| 1      | her2  | 40,244   |
| 2      | erbb2 | 9,929    |
| 3      | “neu gene” | 887 |
| 4      | “epidermal growth factor receptor 2” | 43,228 |
| 5      | #1 OR #2 OR #3 OR #4 | 66,477 |
| 6      | “her2 vaccine” | 54 |
| 7      | “cancer vaccine” | 14,660 |
| 8      | “nelipepimut s” | 100 |
| 9      | “peptide vaccine” | 4,070 |
| 10     | #6 OR #7 OR #8 OR #9 | 17,673 |
| 11     | #5 AND #10 | 940 |
| 12     | #11 AND [embase]/lim NOT ([embase]/lim AND [medline]/lim) | 331 |

**Notes:** Number of studies in the database containing the query term. PubMed Search String ([PubMed.gov](https://www.pmed.gov)): (((dHER2 OR HER2 OR HER2/neu OR “Receptor, ErbB-2”[Mesh] OR human epidermal growth factor receptor 2 OR her OR erbb2 OR neu Gene OR NEU proto-oncogene OR neu receptor OR TKR1)) AND (Her2 Vaccine OR Cancer Vaccines[Mesh] OR Cancer Vaccines OR NeuVax OR Peptide cancer vaccines OR peptide vaccines OR Nelipepimuts OR GP2 OR AE37 OR “E7S” OR E7S HER2-derived peptide vaccine, nelipepimut-S OR whole cell vaccine OR CHP-HER2 vaccine [Supplementary Concept]). Embase Search String ([Embase.com](https://www.embase.com)): ((her2 OR erbb2 OR “neu gene” OR “epidermal growth factor receptor 2”) AND (her2 vaccine OR “cancer vaccine” OR “nelipepimuts” OR “peptide vaccine”)) AND [embase]/lim NOT ([embase]/lim AND [medline]/lim).

### Table S4 Cochrane search strategy and results (Cochrane search string)

| Number | Query | Results* |
|--------|-------|----------|
| 1      | HER2  | 2,933    |
| 2      | MeSH descriptor: [Cancer Vaccines] explode all trees | 294 |
| 3      | #1 and #2 | 6 |

**Note:** Obtained on February 8, 2018.